Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
February 25, 2002
- Very Confident of Our Future in Japan: Mr Payne of Pharmacia
February 25, 2002
- Hodanren Sets Up Cooperative Generics Purchasing System
February 25, 2002
- Sales Increase by 14.1% to \75 Bil.: Nippon Roche
February 25, 2002
- Novartis: Sales Up 14% to CHF32 Bil.
February 25, 2002
- 50,000 Long-admitted Elderly May Be Transferred to Nursing Care Insurance
February 25, 2002
- Tanabe Licenses Tanatril to aaiPharma
February 25, 2002
- GPs Are Reluctant to Conduct H. pylori Eradication Therapy: JGCA Meeting
February 25, 2002
- Dainippon to Mark Record-high Sales, Profits Again
February 25, 2002
- GLs for Proper Use of Anticancer Drugs Presented: Meeting
February 25, 2002
- BUSINESS NEWS IN BRIEF
February 25, 2002
- Treatment GLs for Hyperuricemia, Gout Announced: Society Meeting
February 25, 2002
- WEBSITE NEWS
February 25, 2002
- 700 Renal Transplants Performed in 2001: Meeting
February 25, 2002
- Details of FY2002 NHI Pricing System Reform Approved by Chuikyo
February 25, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 25, 2002
- NHI Pricing System Needs Reform from Mid-, Long-term Perspectives: EAD Director, FPMAJ
February 25, 2002
- Japanese Language Books
February 25, 2002
- LDP Listens to Industry's Views on Pharmaceutical Regulations
February 25, 2002
- Consumers' Interest in Self-medication Increases: PAJ Survey
February 25, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…